Investor hopes were similarly high, so it's little wonder those folks were bearish on Novo Nordisk. They also punished fellow obesity drug developers like Eli Lilly in a sympathy sell-off.

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Presiding over the upward trajectory of Eli Lilly over the last eight years has been paying off nicely for CEO David Ricks. In 2024, his compensation package grew to $29.2 million, according to ...

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound. The Indiana-based drugmaker is slashing the prices of its 2.5 mg ...

Eli Lilly and Co. Wednesday announced plans to build four pharmaceutical manufacturing sites in the United States, significantly boosting domestic medicine production and adding around 13,000 ...

Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier. Ricks' payout included $19.7 million in ...

Earlier this week, Eli Lilly partnered up with telehealth providers ... By integrating with LillyDirect, we are reducing barriers to high-quality care and helping our members afford transformative ...

In some cases, however, it can make sense to buy a stock that's trading at a seemingly high P/E multiple simply ... For years, Eli Lilly has been generating solid growth numbers -- but lately ...

We recently compiled a list of the 20 High Growth Mega Cap Stocks ... Jim Cramer Backs Eli Lilly (LLY): Will Its Drug Pipeline Dominate Pharma? An array of pharmaceutical pills with the company's logo ...

Obesity drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) have found themselves in two contrasting positions as Robert F. Kennedy Jr., a leading critic of weight loss drugs, takes the helm of ...

New results show Eli Lilly (LLY) and Company’s Ebglyss achieved ... 13 inhibitor that selectively blocks IL-13 signaling with high binding affinity. The cytokine IL-13 is a primary cytokine ...